Adage Capital Partners’s EyePoint Pharmaceuticals EYPT Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $64M | Buy |
6,800,000
+600,000
| +10% | +$5.65M | 0.11% | 183 |
|
|
2025
Q1 | $33.6M | Buy |
6,200,000
+450,000
| +8% | +$2.44M | 0.06% | 303 |
|
|
2024
Q4 | $42.8M | Buy |
5,750,000
+1,958,580
| +52% | +$14.6M | 0.07% | 244 |
|
|
2024
Q3 | $30.3M | Buy |
3,791,420
+200,000
| +6% | +$1.6M | 0.05% | 339 |
|
|
2024
Q2 | $31.2M | Sell |
3,591,420
-1,164,879
| -24% | -$10.1M | 0.06% | 324 |
|
|
2024
Q1 | $98.3M | Buy |
4,756,299
+289,879
| +6% | +$5.99M | 0.19% | 114 |
|
|
2023
Q4 | $103M | Buy |
4,466,420
+2,729,917
| +157% | +$63.1M | 0.21% | 108 |
|
|
2023
Q3 | $13.9M | Sell |
1,736,503
-45,749
| -3% | -$366K | 0.03% | 494 |
|
|
2023
Q2 | $15.5M | Sell |
1,782,252
-167,748
| -9% | -$1.46M | 0.03% | 474 |
|
|
2023
Q1 | $5.73M | Hold |
1,950,000
| – | – | 0.01% | 695 |
|
|
2022
Q4 | $6.83M | Hold |
1,950,000
| – | – | 0.02% | 716 |
|
|
2022
Q3 | $15.4M | Hold |
1,950,000
| – | – | 0.04% | 502 |
|
|
2022
Q2 | $15.3M | Hold |
1,950,000
| – | – | 0.04% | 535 |
|
|
2022
Q1 | $23.7M | Hold |
1,950,000
| – | – | 0.05% | 406 |
|
|
2021
Q4 | $23.9M | Buy |
1,950,000
+186,969
| +11% | +$2.29M | 0.04% | 404 |
|
|
2021
Q3 | $18.4M | Buy |
1,763,031
+163,031
| +10% | +$1.7M | 0.04% | 488 |
|
|
2021
Q2 | $14.4M | Buy |
1,600,000
+81,789
| +5% | +$735K | 0.03% | 584 |
|
|
2021
Q1 | $15.4M | Buy |
+1,518,211
| New | +$15.4M | 0.03% | 546 |
|